Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled Study

Carrión, J.A.; Navasa, Miquel; García–Retortillo, Montserrat; García‐Pagán, Juan Carlos; Crespo, Gonzalo; Bruguera, Miquel; Bosch, Jaime; Forns, Xavier

doi:10.1053/j.gastro.2007.03.041

Cited by 333 publications

(320 citation statements)

References 27 publications

Supporting

Mentioning

300

Contrasting

Unclassified

Order By: Relevance

“…The response rate to antiviral therapy with Peg-IFNa with or without RBV is lower in the transplant population. [74][75][76] Also post-transplant patients have relatively more side effects and poor tolerance to combination antivirals. The arrival of DAA allows IFNa-free treatment regimen in HCV-infected liver transplant recipients (LTR).…”

Section: Management Of Hcv Infection After Liver Transplant (Lt)mentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

Section: Management Of Hcv Infection After Liver Transplant (Lt)mentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…However, if adherence can be maintained, similar treatment outcome as in non-transplanted patients may be expected, i.e. patients infected with HCV genotypes 2 or 3 generally having more favourable outcomes than those infected with genotypes 1 or 4 [71].…”

Section: Combination Therapy After Liver Transplantationmentioning

confidence: 99%

Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations

Lagging

Wejstål

Uhnoo

et al. 2009

Scandinavian Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…This can be mitigated by achievement of an SVR with PEG-IFN plus RBV therapy [94]. However, many patients cannot tolerate curative doses or do not respond to therapy [93][94][95]. Therefore, as it would be ideal to be able to predict which patients would benefit from PEG-IFN plus RBV therapy for recurrent HCV, it was recently reported that variants of the SNPs in or around the IL-28B gene from liver donors are also strongly associated to the degree of graft inflammation and the response to therapy of HCV-infected liver recipients [96][97][98].…”

Section: Molecular Epidemiology Of Hcv-relatedmentioning

confidence: 99%

Evolving Trends in the Hepatitis C Virus Molecular Epidemiology Studies: From the Viral Sequences to the Human Genome

Trinks

Gadano

Argibay

2012

Epidemiology Research International

View full text Add to dashboard Cite

Hepatitis C virus (HCV) represents a major worldwide public health problem. The search for the key molecular biomarkers that may provide insight on the basis of the differences in disease progression, severity, and response to therapy is crucial for understanding the natural history of HCV, for estimating the burden of infection and for developing preventive interventions. Initially, molecular epidemiology studies have focused on studying the viral genetic diversity (genotypes, genetic variants, specific nucleotide and amino acid substitutions). However, the clinical heterogeneities of HCV infection and the imperfect predictability of the response to treatment have suggested the need to search for host genetic biomarkers. This led to the discovery of genetic polymorphisms playing a major role in the evolution of infection, as well as in treatment response and adverse effects, such asIL-28B,ITPA, andIP-10. As a consequence, nowadays the focus of molecular epidemiology studies has turned from the viral to the human genome. This paper will cover recent reports on the subject describing the most relevant viral as well as host genetic risk factors analyzed by past and current HCV molecular epidemiology studies.

show abstract

Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled Study

Cited by 333 publications

References 27 publications

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations

Evolving Trends in the Hepatitis C Virus Molecular Epidemiology Studies: From the Viral Sequences to the Human Genome

Contact Info

Product

Resources

About